Safety Study of BMS-823778 in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on fasting plasma glucose (FPG).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus

• Drug naive or on stable metformin therapy

• HbA1c 7-10%

• FPG ≤ 240mg/dL

Exclusion Criteria:

• History of myocardial infarction, coronary angioplasty or bypass grafts, valvular disease or repair, unstable angina pectoris, transient ischemic attack, or cerebrovascular accidents within six months prior to entry into the study

• Congestive heart failure

• Active liver disease

• Impaired renal function

• Hepatitis C, B and HIV

This list is not inclusive; additional information is provided in the protocol